BriaCell Therapeutics Corp. has priced a best-efforts public offering of 5,366,726 units at $5.59 per unit, generating gross proceeds of approximately $30 million before placement agent fees and offering expenses. Each unit consists of one common share (or a Pre-Funded Warrant in lieu thereof) and one warrant. The warrants, approved for listing on the Nasdaq Capital Market under the symbol BCTXL, will be immediately exercisable at $6.93 per share and expire five years from issuance. The offering is expected to close on January 15, 2026, subject to customary closing conditions. BriaCell intends to deploy net proceeds to fund working capital, general corporate purposes and advancement of its immunotherapy programs. ThinkEquity is acting as sole placement agent.

In the Phase 1/2a Bria-OTS study, a 78-year-old patient with hormone receptor-positive, HER2-negative metastatic breast cancer experienced a 100% resolution of a lung metastasis following four doses of Bria-OTS monotherapy. The response was first observed at two months and has been confirmed at four, six and now eleven months, with no treatment-limiting toxicities reported. The patient completed 17 cycles over 12 months and remains in survival follow-up. With the dose escalation phase complete, the trial has entered a Phase 2a cohort evaluating Bria-OTS in combination with an immune checkpoint inhibitor. These results support further development of Bria-OTS as a personalized off-the-shelf immunotherapy for patients with limited treatment options.